Butterfly Learnings Secures Rs 65 Crore to Revolutionize Pediatric Neurocare in India
August 21, 2026, 3:38 pm
Butterfly Learnings, an Indian paediatric healthcare platform, secured Rs 65 crore in pre-Series B funding. Inflexor Ventures led the round. The company focuses on neurodevelopmental conditions like autism and ADHD. Funds will expand over 90 centers across India. It will also strengthen its technology, integrate AI, and commercialize the Get SET Early autism screening solution. This investment addresses fragmented care and delayed diagnoses for 45 million children. Butterfly Learnings aims for coordinated, tech-driven interventions, standardizing clinical protocols. This scaling initiative targets urgent market needs, boosting access to specialist care and therapist training nationwide.
Butterfly Learnings, an emerging leader in paediatric behavioural healthcare, recently secured Rs 65 crore. This pre-Series B funding round signifies substantial investor confidence. Inflexor Ventures spearheaded the investment. Other existing investors, including Enzia Ventures, Insitor Impact Asia Fund, and IIMA Ventures, also participated. This capital infusion targets critical expansion. It aims to elevate neurodevelopmental care across India.
India faces a significant challenge. Approximately 45 million children live with neurodevelopmental conditions. These include autism spectrum disorder, ADHD, and learning disabilities. Awareness of these conditions is growing. Yet, access to specialized care remains severely uneven. Many children experience delayed diagnoses. Care pathways are often fragmented. A significant shortage of trained professionals exists. This creates a vast treatment gap.
Butterfly Learnings was founded to bridge this gap. Dr. Sonam Kothari, a paediatric neurologist, and Dr. Abhishek Sen, a healthcare entrepreneur, launched the company in 2021. They identified a core problem: fragmentation. Diagnosis, therapy, and schooling often operate independently. This disconnect prevents coordinated, effective treatment. No single entity takes responsibility for a child's complete care journey.
The platform addresses this issue comprehensively. It integrates various services under one umbrella. These include clinical therapy, diagnostics, and digital therapeutics. Inclusive schooling forms another key component. Technology-enabled interventions provide further support. The goal is a coordinated care pathway for families. This approach aims to simplify a complex, often overwhelming, process.
A significant portion of the new funding will fuel expansion. Butterfly Learnings plans to grow its network of centers across India. The company currently operates over 90 centers. These span 22 Indian cities. More locations mean broader access. This directly tackles the uneven distribution of specialist care.
Technology is central to Butterfly Learnings' strategy. The investment will strengthen its existing tech platform. It will also fund new artificial intelligence capabilities. AI can enhance diagnostic precision. It can personalize therapy plans. AI integration promises more efficient and effective interventions.
A key focus lies on early intervention. The company developed Get SET Early. This proprietary autism screening solution uses eye-tracking technology. It targets children aged between 12 and 48 months. Early identification is crucial for better outcomes. The new capital will commercialize and deploy this tool more widely. Partnerships with hospitals and paediatricians will facilitate this rollout. They will connect more families to timely screening.
The shortage of trained therapists is a major bottleneck. Butterfly Learnings addresses this through its in-house training program. The funding will scale this program. Expanding the therapist network is vital. It ensures the delivery of high-quality, standardized care. The company currently boasts over 400 therapists and specialists. Growing this number directly impacts service capacity.
Inflexor Ventures' investment reflects broader market trends. There is rising investor interest in specialized healthcare platforms. These platforms combine technology with measurable outcomes. Butterfly Learnings demonstrates this model effectively. It offers standardized, outcome-tracked care at scale. Its founders bring deep clinical expertise and strong execution capabilities. These factors make it an attractive venture.
Butterfly Learnings operates with a clear vision. It prioritizes standardized clinical protocols. Rigorous clinical data guides every decision. Technology underpins the delivery of evidence-based outcomes. Empathy and transparency remain core values. This commitment ensures ethical and effective treatment.
The company's growth trajectory is notable. It reported revenue of Rs 15.5 crore in the financial year ending March 2025. This marked a significant 143.7% increase from the previous year. While it reported a net loss of Rs 13.3 crore in FY25, this is common for high-growth startups investing heavily in expansion. This financial performance underscores its rapid market penetration.
This pre-Series B round follows a Rs 32 crore Series A round in 2024. Insitor Impact Asia Fund II and Enzia Ventures led that previous investment. IIMA Ventures, Foundation Botnar, 9Unicorns, and Venture Catalysts also participated. Consistent funding demonstrates sustained investor belief in the company's mission and model.
The current funding marks a pivotal moment. It enables Butterfly Learnings to significantly scale its impact. Millions of children in India still lack adequate neurodevelopmental support. The company's comprehensive, tech-driven approach offers a beacon of hope. It promises a future with more coordinated care, earlier diagnoses, and better outcomes for neurodivergent children across the nation.
Butterfly Learnings, an emerging leader in paediatric behavioural healthcare, recently secured Rs 65 crore. This pre-Series B funding round signifies substantial investor confidence. Inflexor Ventures spearheaded the investment. Other existing investors, including Enzia Ventures, Insitor Impact Asia Fund, and IIMA Ventures, also participated. This capital infusion targets critical expansion. It aims to elevate neurodevelopmental care across India.
India faces a significant challenge. Approximately 45 million children live with neurodevelopmental conditions. These include autism spectrum disorder, ADHD, and learning disabilities. Awareness of these conditions is growing. Yet, access to specialized care remains severely uneven. Many children experience delayed diagnoses. Care pathways are often fragmented. A significant shortage of trained professionals exists. This creates a vast treatment gap.
Butterfly Learnings was founded to bridge this gap. Dr. Sonam Kothari, a paediatric neurologist, and Dr. Abhishek Sen, a healthcare entrepreneur, launched the company in 2021. They identified a core problem: fragmentation. Diagnosis, therapy, and schooling often operate independently. This disconnect prevents coordinated, effective treatment. No single entity takes responsibility for a child's complete care journey.
The platform addresses this issue comprehensively. It integrates various services under one umbrella. These include clinical therapy, diagnostics, and digital therapeutics. Inclusive schooling forms another key component. Technology-enabled interventions provide further support. The goal is a coordinated care pathway for families. This approach aims to simplify a complex, often overwhelming, process.
A significant portion of the new funding will fuel expansion. Butterfly Learnings plans to grow its network of centers across India. The company currently operates over 90 centers. These span 22 Indian cities. More locations mean broader access. This directly tackles the uneven distribution of specialist care.
Technology is central to Butterfly Learnings' strategy. The investment will strengthen its existing tech platform. It will also fund new artificial intelligence capabilities. AI can enhance diagnostic precision. It can personalize therapy plans. AI integration promises more efficient and effective interventions.
A key focus lies on early intervention. The company developed Get SET Early. This proprietary autism screening solution uses eye-tracking technology. It targets children aged between 12 and 48 months. Early identification is crucial for better outcomes. The new capital will commercialize and deploy this tool more widely. Partnerships with hospitals and paediatricians will facilitate this rollout. They will connect more families to timely screening.
The shortage of trained therapists is a major bottleneck. Butterfly Learnings addresses this through its in-house training program. The funding will scale this program. Expanding the therapist network is vital. It ensures the delivery of high-quality, standardized care. The company currently boasts over 400 therapists and specialists. Growing this number directly impacts service capacity.
Inflexor Ventures' investment reflects broader market trends. There is rising investor interest in specialized healthcare platforms. These platforms combine technology with measurable outcomes. Butterfly Learnings demonstrates this model effectively. It offers standardized, outcome-tracked care at scale. Its founders bring deep clinical expertise and strong execution capabilities. These factors make it an attractive venture.
Butterfly Learnings operates with a clear vision. It prioritizes standardized clinical protocols. Rigorous clinical data guides every decision. Technology underpins the delivery of evidence-based outcomes. Empathy and transparency remain core values. This commitment ensures ethical and effective treatment.
The company's growth trajectory is notable. It reported revenue of Rs 15.5 crore in the financial year ending March 2025. This marked a significant 143.7% increase from the previous year. While it reported a net loss of Rs 13.3 crore in FY25, this is common for high-growth startups investing heavily in expansion. This financial performance underscores its rapid market penetration.
This pre-Series B round follows a Rs 32 crore Series A round in 2024. Insitor Impact Asia Fund II and Enzia Ventures led that previous investment. IIMA Ventures, Foundation Botnar, 9Unicorns, and Venture Catalysts also participated. Consistent funding demonstrates sustained investor belief in the company's mission and model.
The current funding marks a pivotal moment. It enables Butterfly Learnings to significantly scale its impact. Millions of children in India still lack adequate neurodevelopmental support. The company's comprehensive, tech-driven approach offers a beacon of hope. It promises a future with more coordinated care, earlier diagnoses, and better outcomes for neurodivergent children across the nation.